Penrose TherapeuTx Revenue and Competitors
Estimated Revenue & Valuation
- Penrose TherapeuTx's estimated annual revenue is currently $2M per year.
- Penrose TherapeuTx's estimated revenue per employee is $201,000
Employee Data
- Penrose TherapeuTx has 10 Employees.
- Penrose TherapeuTx grew their employee count by -17% last year.
Penrose TherapeuTx's People
Name | Title | Email/Phone |
---|---|---|
1 | President and CEO | Reveal Email/Phone |
2 | Chief Medical Officer | Reveal Email/Phone |
3 | VP Operations | Reveal Email/Phone |
4 | Research Scientist I | Reveal Email/Phone |
5 | Principal Scientist, Analytical Chemistry | Reveal Email/Phone |
6 | Scientist | Reveal Email/Phone |
Penrose TherapeuTx Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $101.3M | 360 | 20% | $10.8M | N/A |
#2 | $7.6M | 38 | -3% | N/A | N/A |
#3 | $6.6M | 33 | 32% | N/A | N/A |
#4 | $2M | 10 | 25% | N/A | N/A |
#5 | $11.9M | 59 | -6% | N/A | N/A |
#6 | $17.7M | 88 | 7% | N/A | N/A |
#7 | $72M | 358 | 7% | N/A | N/A |
#8 | $101M | 359 | 29% | $764.2M | N/A |
#9 | $7.2M | 36 | 6% | N/A | N/A |
#10 | $5.6M | 28 | 4% | N/A | N/A |
What Is Penrose TherapeuTx?
Penrose TherapeuTx is a U.S.-based pharmaceutical company focused on developing innovative small-molecule therapies for the treatment of advanced cancers. Penrose has pioneered the development of a novel Mitochondrial Modifying Agent (MMA) therapeutic platform designed to generate therapies for difficult to treat cancers through a unique cooperative mechanism of action. Our approach has potential broad applicability across both hematologic and solid tumors.
keywords:N/AN/A
Total Funding
10
Number of Employees
$2M
Revenue (est)
-17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.9M | 10 | 0% | N/A |
#2 | $0.9M | 10 | 11% | N/A |
#3 | $1.5M | 11 | 0% | N/A |
#4 | $1.4M | 11 | 10% | N/A |
#5 | $1.9M | 11 | 22% | N/A |